Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial
Titel:
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial
Auteur:
Lang, Istvan Brodowicz, Thomas Ryvo, Larisa Kahan, Zsuzsanna Greil, Richard Beslija, Semir Stemmer, Salomon M Kaufman, Bella Zvirbule, Zanete Steger, Günther G Melichar, Bohuslav Pienkowski, Tadeusz Sirbu, Daniela Messinger, Diethelm Zielinski, Christoph